eFT 508

Drug Profile

eFT 508

Alternative Names: eFT-508

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Effector Therapeutics
  • Class Antineoplastics
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer; Lymphoma
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 05 Jun 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I part of phase I/II trial in Solid tumours released by eFFECTOR Therapeutics
  • 05 Jun 2017 eFFECTOR Therapeutics plans a phase II trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) and Lymphoma (Monotherapy, Combination therapy)
  • 03 Apr 2017 Preclinical pharmacodynamics data in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top